Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03772665 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Emixustat in Stargardt Disease
A Phase 3 study, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 3
- Development phase
- 194
- Enrollment target
NCT03772665: Completed Phase 3 study, sponsored by Kubota Vision.
NCT03772665 is a Phase 3 study that has completed, run by Kubota Vision. The registered enrollment target is 194 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03772665, a Phase 3 study, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 194 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD
Primary Outcome
Mean rate of change in total area of macular atrophy, as measured by fundus autofluorescence (FAF)
Interventions
- DRUG Placebo
- DRUG Emixustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2022-06-23 |
| Phase | Phase 3 |
What the finished NCT03772665 record still lists
NCT03772665 is an interventional study that assigns participants to a tested intervention. The registered 194 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03772665 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03772665 about?
NCT03772665 is a clinical study titled "Safety and Efficacy of Emixustat in Stargardt Disease". The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD
What is the current status of trial NCT03772665?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 194 participants. The study started on 2019-01-07. Estimated completion is 2022-06-23.
What interventions are being tested in trial NCT03772665?
The interventions under investigation include: Placebo (DRUG), Emixustat (DRUG).
Who is sponsoring clinical trial NCT03772665?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03772665's enrollment target sits among peer trials
194 1395th of 2000 higher than 604 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
- NCT05351424 · 194 participants · NA
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI